Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.
Gene mutations offer clues about which advanced lung cancer patients may face shorter survival with current treatments.
This phase 2 clinical trial evaluates Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study. The PubMed abstract reports that Presence of a TP53 mutation was associated with shorter OS in all cohorts.
What the study was
- Study design
- Phase 2 clinical trial
- Population
- Human participants described in the PubMed abstract
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Why it surfaced
Phase 2 clinical trial with human evidence; scored conservatively from PubMed abstract-level metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.